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NEWS
NCATS Introduces Plans for 
New Single IRB Reliance Platform
On May 2, 2016, NCATS held a workshop for Clinical and Translational
Science Awards (CTSA) Program representatives and other innovators in
clinical research management to educate them about using its new single
institutional review board (IRB) reliance platform for multisite clinical
studies. The NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART)
IRB Reliance Platform is based on the successful experiences of NIH single IRB initiatives and on
CTSA Program demonstration projects using a model called IRBrely. Designed to be a flexible platform
that will enable harmonization and streamlining of processes, the NCATS SMART IRB Reliance Platform
will be a key component of NCATS' Trial Innovation Network. In addition, NCATS intends for the platform to
serve as a roadmap for the nation to help implement NIH's policy on single IRB use in multisite studies
and as a resource for clinical researchers who conduct these studies.
Read More
Academic Job Search Series
Provided by the UMMS Center for Biomedical Career Development
Part 2:  Writing Your Statement of Teaching Philosophy
Monday, July 18, 2016
12:00 - 2:00 pm
S2-310, 2nd floor conference room, UMMS
Part 3:  Preparing for the Interview Visit
Part 4:  Negotiating Your Startup Package
Wednesday, August 10, 2016
Part 3, 10:00 - 11:30 am
Part 4, 11:30 am - 1:00 pm
S2-310, 2nd floor conference room, UMMS
Questions or Comments?   Please email GSBScareer@umassmed.edu
Teaching of Tomorrow (TOT)
Enhancing Clinical Teaching Skills through 
Discourse and Practice
Sponsored by the Clinical Faculty Development Center, 
UMass Medical School
4-Day Course to be held on:
November 18-19, 2016 AND March 10-11, 2017
Teaching of Tomorrow (TOT) is a nationally recognized and highly acclaimed Faculty Development
Program for preceptors of medical students and residents. First offered in 1994, this program is presented
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by UMass faculty from the departments of Family Medicine, Internal Medicine and Pediatrics; over 1,500
clinical faculty and preceptors throughout the Northeast and beyond have participated. The course is
designed for clinicians from any specialty--anyone who is interested in refining their clinical teaching
skills and networking with other clinician educators.
Read More
Sharing Our Stories - Just Like NIH
Sally Gore, MS, MSLIS
Research Evaluation Analyst, UMCCTS
Carrie Wolinetz, Ph.D., Associate Director for Science Policy at NIH begins her June 1 blog post with the
following:
 
Let me pose a simple question - how do we know if NIH is achieving its mission? It's tricky enough to
assess how effective we are at generating fundamental scientific knowledge, though we have a
decent grasp on that side of the equation. We can link tens of thousands of biomedical research
articles published each year to the NIH grants that supported them. But can we take it a few sizeable
steps further and systematically connect our research efforts to advances in human health? And how
can we use what we learn to design policies and strategies to speed innovation and biomedical
progress?
 
Here at the UMCCTS, we ask ourselves the same questions and we grapple with the same trickiness of
the situation to find the right answers. One thing that NIH has done to address the issue is launch a
website, Impact of NIH Research, and more recently, added the "Our Stories" section to it. The section
debuted this month with 3 case studies:
Read More
DID YOU KNOW?
PubMed Health
Sally Gore, MS, MSLIS
Research Evaluation Analyst, UMCCTS
It's hard to imagine that there are many readers of this newsletter who don't know about PubMed, but do
you know PubMed Health? PubMed Health (PMH) is another resource from the National Center for
Biotechnology Information (NCBI), a division of the National Library of Medicine (NLM). Its goal is to provide
clinicians and patients with fast, easy access to credible health information on the prevention and treatment
of diseases and conditions. Focusing on clinical effectiveness research, it specializes in collecting and
indexing systematic reviews of clinical trials - both the full versions, as well as summaries that are easier
for the public to understand. A number of authoritative sources provide the reviews to PMH including the
Agency for Healthcare Research and Quality (AHRQ), the National Cancer Institute, the Department of
Veterans Affairs, and Cochrane, the latter being the gold standard of systematic reviews. The database
goes back to approximately 2003 and is updated daily with new reviews and articles. If you're looking for a
quick way to locate reviews of clinical trials, next time remember to try PubMed Health.
EVENTS
 June 2016 Events
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Alex K. Shalek, PhD
Hermann L.F. Von Helmholtz Career Development Professor, HST
Assistant Professor, Department of Chemistry, MIT (http://shalek.wpengine.com/)
"Immunology from the 'Bottom-Up' with Single-Cell Genomics"
Thursday, June 16, 2016
11:00 am
Albert Sherman Center, 6th Floor Conference Room AS6-2072
University of Massachusetts Medical School
Host: Manuel Garber, PhD, Associate Professor Bioinformatics and Integrative Biology; Director,
Bioinformatics Core, UMMS
Raj Kalkeri, PhD
Project Leader, In Vitro Antiviral Drug Development, Department of Infectious Disease
Research, Southern Research Institute
Pharma experience includes Vertex Pharmaceuticals
Pharmacological Studies: Not Just a "Furry Test Tube"
Thursday, June 16, 2016
Albert Sherman Center
Multi-Purpose Room EAST, 1st floor
University of Massachusetts Medical School
4:00 - 5:00 pm - Lecture and Case Study
5:00 - 5:30 pm - Networking (refreshments served)
Lecture and Case Study:  This lecture will discuss why the FDA requires animal models for most
therapeutic indications and what we hope to learn from animal studies that we can't learn from in vitro
experiments in a test tube. The speaker will discuss the limitations of animal models and ethical
considerations in the use of animals, from zebra fish to non-human primates. The speaker will also
describe the development of an animal model for drug discovery, how it was used and what was learned.
Registration is still open.  Register today or walk-in. You're welcome to join.
This event will be a great opportunity for networking and collaboration too!
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Molecular Medicine Distinguished Lecture
Evan Rosen, MD, PhD
Professor of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
Evan Rosen Laboratory
"Epigenomic Approaches to Adipose Tissue Biology"
Thursday, June 30, 2016
12:00 pm
Molecular Medicine Seminar Room, 3rd Floor
Biotech II, 373 Plantation Street, UMMS, Worcester, MA
Host: Michael Czech, PhD, Chair and Professor, Program in Molecular Medicine, UMMS
Human Research Protection Program (HRPP)
Upcoming Educational Opportunities
Clinical Research Professionals Group (CRPG) Meetings:
Thursday, July 14, 2016
1:00 - 2:00 pm
Hiatt Auditorium, S1-608, UMMS, Worcester
Friday, August 12, 2016
10:00 - 11:00 am
Hiatt Auditorium, S1-608, UMMS, Worcester
Learn More
FUNDING and TRAINING OPPORTUNITIES
Pipeline to Proposals Awards Initiative
Call for Letters of Intent
The Patient-Centered Outcomes Research Institute (PCORI) is seeking
Letters of Intent for Independent Tier III projects through their Pipeline to
Proposals Awards Initiative. This program supports the development of
research proposals designed by research partnerships of researchers,
patients, caregivers, and other healthcare stakeholders.
The purpose of the Pipeline to Proposals Initiative is to cultivate the development of proposals with sound
scientific rigor and robust patient engagement. PCORI expects the Pipeline to Proposals project will
help individuals strengthen collaborations that can produce meaningful research proposals. Applicants
must be research partnerships including at least one patient and at least one researcher. Up to $50,000
for up to a Nine-Month Project Term.
Deadline for submitting a letter of intent is Thursday, June 30, 2016
Learn More
Solicitation of Assays for the 4
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UMASS-Chemical Screening Initiative
The UMASS-Chemical Screening Initiative (UMASS-CSI) provides
investigators access to experienced professional and state-of-the-art
technological resources at the Small Molecule Screening Facility (SMSF) for
the discovery of exceptional chemical probes, potential diagnostic and
therapeutic candidates of high impact, as well as research tools. The program
is funded by the UMass Office of the President's Science and Technology
Fund.
The objective of this solicitation is to invite applicants with a well-developed
assay used in basic research and therapeutic development programs
suitable for HTS to submit the assay for consideration by the UMASS-CSI to
identify hits and probes from the SMSF compound library.
Tier 1 projects encompassing pilot experiments would be awarded $7,250 each for screening any
library of choice, up to a total of 5,000 compounds (e.g., a partial Diversity set and/or a combination of the
LOPAC and international drug collection to name a few)
Tier 2 projects would involve comprehensive screening of the entire 58,000 compound library. Tier 2
projects would be awarded $22,500 each.
Proposal Deadline:  July 1, 2016
Learn More
Do you have a transformational advancement in
diabetes research?
The Diabetes Innovation Challenge is now seeking
qualified applicants for an exciting competition!
T1D Exchange and M2D2 are pleased to announce an open competition to
identify and accelerate transformational advancements in diabetes research and care.
The Diabetes Innovation Challenge will provide up to two awards of up to $150,000 in cash or in-kind
services provided by T1D Exchange, M2D2, and Challenge sponsors, including JDRF, the leading global
organization funding type 1 diabetes research.
July 8, 2016 - Deadline to submit initial application
Learn More
World Without Disease QuickFire Challenges
Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. are looking for the
best idea, technology or solution to award $500,000. The JLABS QuickFire
Challenges are competitions designed to attract game-changing, early-stage
innovation in the Therapeutics, Consumer, Health Technologies and Med Device
sectors. Winners will be awarded a variety of prizes (including cash and/or lab
space), benefit from world-class lab facilities, be supported by an onsite team and
have access to a global network of industry experts and programming.
Deadline to apply is August 31, 2016
Learn More
University of Massachusetts Medical School
Transdisciplinary Training in 
Cardiovascular Research (T32)
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UMass has a cardiovascular T32 training grant entitled
"Transdisciplinary Training in Cardiovascular Research" under
the direction and senior leadership of Drs. Catarina Kiefe and John
Keaney.  The program represents a wonderful opportunity for the institution
to promote the entire spectrum (T0-T2+) of cardiovascular research on our campus.  We are writing to
request applications from trainees who wish to become part of this exciting program at the postdoctoral
level. New trainees will join 4 other current trainees in the program.
Eligibility:  Please see http://grants.nih.gov/grants/guide/pa-files/PA-14-015.html
Duration of support: Funding for two years of support provided.  Trainees may apply for an additional
year.
 
Amount of support: Based upon the NIH stipend schedule as outlined in the link below.  Faculty
sponsors may, at their discretion and with department and institutional approval supplement the NIH
stipend, but only from a non-federal, non-sponsored funding source.
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-048.html
Proposals are accepted on a rolling basis.
Learn More
Allied Minds and Bristol-Myers Squibb announce...
CATALYST
CATALYST is an exciting new program launched by Allied-Bristol Life Sciences (ABLS), a joint venture of
global pharmaceutical company Bristol-Myers Squibb and venture builder Allied Minds, to identify and
develop commercially-promising biopharmaceutical innovations from leading universities and research
institutions.  Launched in 2014, ABLS provides world-class expertise in drug development, access to a
fully integrated drug discovery and development center (with medicinal chemistry, biological assays,
animal models, pharmacology, toxicology capabilities, etc.) as well as seasoned management and the
necessary financial backing to bring transformational academic discoveries to patients.
 
ELIGIBILITY
The Principal Investigator of a CATALYST proposal must be available to collaborate with ABLS in the
translation of their discovery.
 
SELECTION CRITERIA AND PROCESS
Successful proposals will have elucidated novel and differentiated mechanisms, supported by
strong scientific validation, underlying disease states of strategic interest (see below). Priority will be
given to those projects where initial lead molecules have already been identified and possess the
potential to deliver first-in class drug candidates.
Proposals are accepted on a rolling basis. Proposals submitted by the 1st of each
month are reviewed on or before the 28th of the same month. PIs of selected proposals will be
invited to present their projects to the CATALYST Steering Committee. If your project is selected, we
will work efficiently with you to finalize the research plan, budget, and necessary agreements.
Learn More
Cont...Sharing Our Stories - Just Like NIH
Childhood Hib Vaccines: Nearly Eliminating the Threat of Bacterial Meningitis
Neurostimulation Technologies: Harnessing Electricity To Treat Lost Neural Function
Fighting Cancer: Ushering in a New Era of Molecular Medicine
 
Each of these resources provides a concise overview and informative graphic that tells the story of when
and how the particular research achieved its goal(s). As a package, they can be used to inform NIH's
stakeholders of the concrete impact that its research had on human health.
 
The UMCCTS also seeks to collect and track the information needed to tell our own stories of success. The
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Performance Metrics page on our website summarizes and complements the many progress reports we
receive from the cores and programs we sponsor, helping us to better show the impact of the clinical and
translational science being done across the 5 UMass campuses. They can be downloaded and shared
with stakeholders when needed, to show how how our programs advance scientifica and clinical
knowledge, and make a difference in improving health.
 
We're always looking for stories to tell and are happy to help you come up with your own. Please explore
what's been accomplished to date and consider adding your stories to the big picture.
The UMass Center for Clinical and Translational Science (UMCCTS) was founded in 2006 to enhance clinical and
translational research across the five University of Massachusetts campuses and our clinical partner, UMass Memorial
Health Care. With the receipt of an NIH Clinical and Translational Science Award (CTSA) in 2010, and its successful
renewal in 2015, the UMCCTS joined a network of 62 NIH-funded centers collaborating to transform the conduct of clinical
and translational research across the U.S. Other key partners include our patients and communities, foundations,
biotechnology and pharmaceutical companies, and members of the venture capital and philanthropic communities.
We encourage you to browse through our website to learn more about how the UMCCTS catalyzes clinical and
translational research through education and training, pilot funding programs, cores, and services.
Please remember to cite the CTSA Grant # UL1-TR001453 in all supported journal publications.
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